Prima BioMed Ltd. announced that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761. This antibody, developed at the company's laboratory in Châtenay-Malabry south of Paris, is believed to be the first agonist antibody of LAG-3. The IMP761 agonist antibody is an exciting new addition to the Prima pipeline of product candidates. It is mechanistically distinct from any of the known LAG-3 antibodies. Prima continues to lead the way in researching and developing novel LAG-3 targeting technologies. IMP761 is a humanised IgG4 monoclonal antibody that has been developed by staff in Prima's laboratory in Paris. A new patent has been filed to provide protection for this antibody. Inflammatory and autoimmune diseases are characterised by activated T cells that react against the patients' own tissues. They fail to switch off when they should and therefore cause tissue destruction or inflammatory responses. Using an agonist antibody that targets the LAG-3 receptor on the surface of activated T cells is expected to result in an inhibitory signal being delivered directly into the T cell to stop it from continuing to proliferate and react against a patient's own tissues.